Components of metabolic syndrome predicting diabetes: No role of inflammation or dyslipidemia

Obesity

Volumn 15, Issue 7, 2007, Pages 1875-1885

  Norberg, Margareta ^a   Stenlund, Hans ^a   Lindahl, Bernt ^a   Andersson, Christer ^a   Weinehall, Lars ^a,b   Hallmans, Gãran ^a   Eriksson, Jan W ^a,c  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Dyslipidemia; Inflammation; Metabolic syndrome; Prediction; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; LEPTIN; PROINSULIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; BLOOD PRESSURE; BODY MASS; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; INFLAMMATION; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; RISK FACTOR; SWEDEN;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HEALTH SURVEYS; HUMANS; INFLAMMATION; LEPTIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROINSULIN; RISK FACTORS; SWEDEN;

EID: 34547930678     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2007.222     Document Type: Article

References (46)

1. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005;48:1684-99.
2. Gale EA. The myth of the metabolic syndrome. Diabetologia. 2005;48:1679-83.
3. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059-62.
4. WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Report of a WHO Consultation. Geneva, Switzerland: World Health Organization; 1999.
5. Grundy SM, Cleeman JI, Daniels SR, et al.Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
6. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care. 2003;26:1297-303.
7. IDF.The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels, Belgium: International Diabetes Federation; 2005.
8. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28.
9. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes. 1997;46:1594-600.
10. Hodge AM, Boyko EJ, de Courten M, et al. Leptin and other components of the metabolic syndrome in Mauritius - a factor analysis. Int J Obes Relat Metab Disord. 2001;25:126-31.
11. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes. 2002;51:3120-7.
12. Hanley AJ, Festa A, D'Agostino RB Jr, et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes. 2004;53:1773-81.
13. Lawlor DA, Ebrahim S, May M, Davey Smith G. (Mis)use of factor analysis in the study of insulin resistance syndrome. Am J Epidemiol. 2004;159:1013-8.
14. Chan JC, Cheung JC, Stehouwer CD, et al. The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome-an analysis by structural equation modelling. Int J Obes Relat Metab Disord. 2002;26:994-1008.
15. Shen BJ, Todaro JF, Niaura R, et al. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol. 2003;157: 701-11.
16. Novak S, Stapleton LM, Litaker JR, Lawson KA. A confirmatory factor analysis evaluation of the coronary heart disease risk factors of metabolic syndrome with emphasis on the insulin resistance factor. Diabetes Obes Metab. 2003;5: 388-96.
17. Wang JJ, Qiao Q, Miettinen ME, Lappalainen J, Hu G, Tuomilehto J. The metabolic syndrome defined by factor analysis and incident type 2 diabetes in a Chinese population with high postprandial glucose. Diabetes Care. 2004; 27:2429-37.
18. Pladevall M, Singal B, Williams LK, et al. A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care. 2006;29:113-22.
19. Hu FB. Re: "Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome". Am J Epidemiol. 2001;153:717-8.
20. Boyko EJ, de Courten M, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KG. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care. 2000;23:1242-8.
21. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care. 2003;26:3153-9.
22. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-9.
23. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112: 3066-72.
24. Kekalainen P, Sarlund H, Pyorala K, Laakso M. Hyperin-sulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes. Diabetes Care. 1999;22:86-92.
25. Weinehall L, Hallgren CG, Westman G, Janlert U, Wall S. Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care. Scand J Prim Health Care. 1998;16:171-6.
26. Essebag V, Genest J Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J. 2003;146:581-90.
27. Norberg M, Eriksson JW, Lindahl B, et al. A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed. J Intern Med. 2006;260:263-71.
28. Norberg M, Stenlund H, Lindahl B, Andersson C, Eriksson JW, Weinehall L.Work stress and low emotional support is associated with increased risk of future type 2 diabetes in women. Diabetes Res Clin Pract. 2007;76:368-77.
29. Weinehall L, Ohgren B, Persson M, et al. High remaining risk in poorly treated hypertension: the 'rule of halves' still exists. J Hypertens. 2002;20:2081-8.
30. Eliasson M, Lindahl B, Lundberg V, Stegmayr B. No increase in the prevalence of known diabetes between 1986 and 1999 in subjects 25-64 years of age in northern Sweden. Diabet Med. 2002;19:874-80.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
32. Meigs JB. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol. 2000;152:908-11.
33. Maruyama G. Basics of Structural Equation Modeling. Thousands Oaks, CA: Sage Publications; 1998.
34. Arbuckle J. AMOS. Chicago, IL: Small Waters Corporation; 1997.
35. Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S25-8.
36. Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596-600.
37. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord. 2003; 27(Suppl 3):S49-52.
38. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflamma tory markers and risk of developing type 2 diabetes in women. Diabetes. 2004;53:693-700.
39. Kriketos AD, Greenfield JR, Peake PW, et al. Inflammation, insulin resistance, and adiposity: a study of first-degree relatives of type 2 diabetic subjects. Diabetes Care. 2004;27: 2033-40.
40. Lin Y, Berg AH, Iyengar P, et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem. 2005;280:4617-26.
41. Lindmark S, Buren J, Eriksson JW. Insulin resistance, endocrine function and adipokines in type 2 diabetes patients at different glycaemic levels: potential impact for glucotoxicity in vivo. Clin Endocrinol (Oxf). 2006;65:301-9.
42. Eriksson JW, Smith U, Waagstein F, Wysocki M, Jansson PA. Glucose turnover and adipose tissue lipolysis are insulin-resistant in healthy relatives of type 2 diabetes patients: is cellular insulin resistance a secondary phenomenon? Diabetes. 1999;48:1572-8.
43. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24:89-94.
44. Lyssenko V, Almgren P, Anevski D, et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005;54:166-74.
45. Pfutzner A, Kunt T, Hohberg C, et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care. 2004;27:682-7.
46. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-5.